Introducing our new pulmonary fibrosis model: Silica-induced pulmonary fibrosis model

Today, we are pleased to announce that we have expanded our preclinical model lineup by including the “Silica-induced pulmonary fibrosis model”.


Pulmonary fibrosis in silica models occurs early and is maintained long term. Hence, this model is one of the most beneficial model mice for therapeutic study for pulmonary fibrosis.

In general, human pulmonary fibrosis does not resolve, whereas fibrosis in bleomycin model, a typical pulmonary fibrosis model, resolves in about 3 weeks after the disease induction. On the other hand, fibrosis in the silica model is persisted for as long as 9 weeks.

The silica model has the property of persistent fibrosis and thus is a complementary model to the bleomycin model in which fibrosis is resolved. So, this model provides a high clinical correlation for therapeutic study for pulmonary fibrosis.


Silica entering the alveoli causes inflammation and long-term interstitial fibrosis. This model mimics human silicosis including the nodule formation that can be observed in it.




If you are targeting IPF or other pulmonary interstitial fibrosis included in the progressive pulmonary fibrosis (PPF), a drug efficacy evaluation study with our silica model would be beneficial.


For those of you who have tried evaluating the drug efficacy with the bleomycin model but would like to obtain data with a different model, we suggest you try evaluating the drug efficacy using silica model.

We also suggest evaluating with the silica model to those who would like to evaluate the drug efficacy in a model of persistent pulmonary fibrosis as well.


Please feel free to contact us if you are interested in our model, including a comparison of our pulmonary fibrosis model with the silica model.